The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival ...
The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...
Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.
The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...
Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.
The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with ...
Results demonstrated a statistically significant and clinically meaningful improvement in progression-free survival ... heterogeneous tumors that originate from the neuroendocrine cells of the ...
Overall survival (OS) data were not mature ... Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute. “This FDA approval marks a ...
The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback